Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antibiotic
|
| gptkbp:approves |
gptkb:FDA
pneumonia skin infections vancomycin-resistant Enterococcus |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Zyvox
|
| gptkbp:clinicalTrials |
well tolerated
compared to vancomycin effective against MRSA |
| gptkbp:contraindication |
monoamine oxidase inhibitors
serotonin syndrome |
| gptkbp:dosageForm |
600 mg
every 12 hours |
| gptkbp:drugInterdiction |
distributes widely in tissues
well absorbed orally |
| gptkbp:formulation |
tablet
suspension injection |
| https://www.w3.org/2000/01/rdf-schema#label |
Zyvox
|
| gptkbp:impact |
10 to 14 days
|
| gptkbp:interactsWith |
antidepressants
serotonergic drugs adrenergic drugs |
| gptkbp:issuedBy |
oral tablet
intravenous injection |
| gptkbp:lastProduced |
2000
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_States |
| gptkbp:numberOfStudents |
4 to 5 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:patentStatus |
patented
|
| gptkbp:research |
combination therapies
resistance patterns ongoing for new indications |
| gptkbp:safety |
not recommended during breastfeeding
pregnancy category C |
| gptkbp:sideEffect |
headache
nausea diarrhea insomnia thrombocytopenia |
| gptkbp:triggerType |
inhibits bacterial protein synthesis
|
| gptkbp:type |
linezolid
|
| gptkbp:usedFor |
treating bacterial infections
|
| gptkbp:waterManagement |
urine
feces |